Kala Pharmaceuticals, Inc. Appoints Todd Bazemore as Chief Operating Officer, Effective on or About November 20, 2017
November 13, 2017 at 08:01 am EST
Share
On November 8, 2017, the Board of Directors of Kala Pharmaceuticals, Inc. appointed Todd Bazemore as Chief Operating Officer of the company effective as of his first date of employment with the company which is expected to be on or about November 20, 2017. Mr. Bazemore served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc., from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp. between April 2014 and January, 2016.
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Companyâs biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Companyâs product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.